Among 31 analysts covering AstraZeneca PLC (LON:AZN), 15 have Buy rating, 3 Sell and 13 Hold.
While looking at the Stock's Performance, AstraZeneca PLC now shows a Weekly Performance of 1.7%, where Monthly Performance is 1.82%, Quarterly performance is 12.83%, 6 Months performance is 25.05% and yearly performance percentage is 25.6%. The stock declined 8.29% or $0.85 reaching $9.4 per share. Deutsche Bank AG reaffirmed a "buy" rating on shares of AstraZeneca plc in a research report on Monday, May 22nd. On average, equities analysts predict that Astrazeneca PLC will post $1.86 earnings per share for the current year. AstraZeneca plc presently has a consensus rating of "Hold" and an average target price of GBX 5,171.80 ($65.89). Finally, Acadian Asset Management LLC raised its stake in shares of Astrazeneca PLC by 1,686.6% in the first quarter. The company has market cap of 68.36 billion GBP. UBS has "Sell" rating and $4 target. The firm has "Buy" rating by Citigroup given on Wednesday, May 25.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The rating was maintained by Societe Generale with "Buy" on Thursday, March 23.
AstraZeneca PLC (AZN) will report its next earnings on Jul 27 BMO.
NDA Presidential candidate Ram Nath Kovind gets NSG security cover
Earlier, Shiv Sena had refrained from spelling out any name for the presidential candidate or taking a stand for Ram Nath Kovind. It had backed Congress nominees - Pratibha Patil and Pranab Mukherjee - in the last two presidential elections .
AstraZeneca PLC closed its last trading session at $34.54 with the gain of 0.29%. AstraZeneca PLC has GBX 7600 highest and GBX 3700 lowest target. They expect $0.44 EPS, down 46.99% or $0.39 from last year's $0.83 per share. The company has a market capitalization of $87.46 billion, a P/E ratio of 25.87 and a beta of 0.81. During the same period previous year, the company earned $0.95 EPS.
AstraZeneca plc (LON:AZN) opened at 5371.00 on Thursday. The target price by Credit Suisse would suggest a potential downside of -7.73 % from the company's stock close price. Liberum Capital decreased their price objective on AstraZeneca plc from GBX 5,200 ($66.25) to GBX 5,100 ($64.98) and set a "buy" rating for the company in a research report on Monday, February 13th. Natixis maintained it with "Neutral" rating and GBX 4456 target in Wednesday, November 4 report. The firm earned "Outperform" rating on Wednesday, August 12 by Robert W. Baird. Baird Financial Group Inc. now owns 52,656 shares of the company's stock valued at $1,439,000 after buying an additional 919 shares during the period. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The company reported $0.99 EPS for the quarter, beating the Zacks' consensus estimate of $0.38 by $0.61. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. The Switzerland-based Banque Pictet & Cie Sa has invested 0% in the stock. Its down 0.79, from 1.63 in 2016Q3. Penn Inc reported 32,475 shares. Brown Brothers Harriman And owns 700 shares or 0% of their U.S. portfolio. Zions Bancorporation (NASDAQ:ZION) was raised too. Ellington Mgmt Group Incorporated Ltd holds 0.02% or 29,500 shares.
Clearbridge Llc increased Legacy Tex Finl Group Inc stake by 96,840 shares to 534,517 valued at $23.02 million in 2016Q4. Barker William E also sold $72,521 worth of Hi-Crush Partners LP (NYSE:HCLP) shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Comments